Every 424B that Atossa Therapeutics, Inc. (ATOS) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow ATOS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ATOS filings page.
Atossa Therapeutics, Inc. is conducting a registered direct primary offering of 1,363,637 shares of common stock, each sold together with one Series A warrant and one Series B warrant, and placement agent warrants. The offering price is $3.30 per share with aggregate gross proceeds of $4,500,002.10. Net proceeds to the company before expenses are presented as $4,185,001.95 and the company estimates net proceeds after fees and expenses of approximately $4.1 million, to be used for clinical development, working capital and general corporate purposes. The warrants (totaling up to 2,727,274 shares) will be exercisable beginning six months after issuance at an exercise price of $4.40 per share; Series A warrants expire in five and one-half years and Series B warrants expire in two years. The placement agent will receive a cash fee equal to 7.0% of gross proceeds and placement agent warrants equal to 3.0% of shares sold to investors. Shares outstanding after the offering are stated as 9,974,997 (excluding shares issuable upon exercise of warrants and placement agent warrants) based on 8,611,361 shares outstanding as of March 31, 2026.
Atossa Therapeutics, Inc. has filed a prospectus supplement to sell up to $50,000,000 of its common stock through an at-the-market offering with Rodman & Renshaw LLC under a Sales Agreement. Sales may occur from time to time on Nasdaq or by other permitted methods and Rodman will receive up to a 3.0% commission on gross sales.
The prospectus notes 8,611,428 shares outstanding as of September 30, 2025 and states that all share and per-share amounts in the supplement reflect a 15:1 reverse stock split effective February 2, 2026. Proceeds, if any, are intended for clinical development, working capital and general corporate purposes; actual proceeds depend on the timing and market prices of sales.
Atos Therapeutics, Inc. amended its ATM facility. The prospectus supplement states the company reduced the Maximum Offering Price under its Open Market Sale with Jefferies LLC from $100,000,000 to $0, effective as of February 20, 2026.
No shares have been sold under the ATM Facility as of the date of the supplement.